Metabolic bioactivation and drug-related adverse effects: Current status and future directions from a pharmaceutical research perspective

Drug Metabolism Reviews

Volumn 42, Issue 2, 2010, Pages 225-249

  Tang, Wei ^a   Lu, Anthony Y H ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Drug metabolism; Drug induced adverse reactions; Hepatotoxicity; Metabolic bioactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINE OXIDASE (FLAVIN CONTAINING); ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A; DESFLURANE; DICLOFENAC; DIPEPTIDYL PEPTIDASE IV; ENFLURANE; ERYTHROMYCIN; ETHINYLESTRADIOL; GESTODENE; HALOTHANE; ISOFLURANE; MIDAZOLAM; MIFEPRISTONE; NEFAZODONE; PARACETAMOL; RALOXIFENE; SIMVASTATIN; TACROLIMUS; TARANABANT; TELITHROMYCIN; TRIAZOLAM; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; XIMELAGATRAN; ZOMEPIRAC;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COVALENT BOND; DISEASE SEVERITY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HEPATITIS; HUMAN; JAUNDICE; LIVER INJURY; LIVER MICROSOME; LIVER MITOCHONDRION; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOTRANSFORMATION; DRUG DISCOVERY; DRUG-INDUCED LIVER INJURY; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEINS;

EID: 77951435259     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602530903401658     Document Type: Review

References (179)

1. Abboud, G., Kaplowitz, N. (2007). Drug-induced liver injury. Drug Saf 30:277-294.
2. Anders, M. W. (2005). Formation and toxicity of anesthetic degradation products. Annu Rev Pharmacol Toxicol 45:147-176.
3. Anders, M. W., Dekant, W. (1998). Glutathione-dependent bioactiva-tion of haloalkenes. Annu Rev Pharmacol Toxicol 38:501-537.
4. AstraZeneca. (2006). Press release. Available at: www.astrazeneca. com/media/latest-press-releases/2006. (Accessed February 7 2009).
5. Baer, B. R., Wienkers, L. C., Rock, D. A. (2007). Time-dependent inac-tivation of P450 3A4 by raloxifene: identifcation of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954-964.
6. Baillie, T. A. (2008). Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Cehm Res Toxicol 21:129-137.
7. Baillie, T. A., Slatter, J. G. (1991). Glutathione\-a vehicle for the transport of chemically reactive metabolites. Acc Chem Res 24:264-270.
8. Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., et al. (2001). Reduced cardiotoxicity and preserved antitumor efcacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454.
9. Baughman, T. M., Graham, R. A., Wells-Knecht, K., Silver, I. S., Tyler, L. O., Wells-Knecht, M., et al. (2005). Metabolic activation of pioglitazone identifed from rat and human liver micro-somes and freshly isolated hepatocytes. Drug Metab Dispos 33:733-738.
10. Bauman, J. N., Frederick, K. S., Sawant, A., Walsky, R. L., Cox, L. M., Obach, R. S., et al. (2008). Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos 36:1016-1029.
11. Beaune, P., Dansette, P. M., Mansuy, D., Kifel, L., Finck, M., Amar, C., et al. (1987). Human anti-endoplasmic reticulum autoantibod-ies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 84:551-555.
12. Benson, M. D., Aldo-Benson, M., Brandt, K. D. (1985). Synovial fuid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Semin Arthr Rheum 15:65-67.
13. Bhaskaran, K., Hamouda, O., Sannes, M., Boufassa, F., Johnson, A. M., Lambert, P. C., et al. (2008). Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300:51-59.
14. Blain, P. G., Battershill, J. M., Venitt, S., Copper, C. C., Fielder, R. J. (1998). Consideration of short-term carcinogenicity tests using transgenic mouse models. Mutat Res 403:259-263.
15. +/- mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 13:982-988.
16. Borzelleca, J. F. (2000). Paracelsus: herald of modern toxicology. Toxicol Sci 53:2-4.
17. Bourdi, M., Chen, W., Peter, R. M., Martin, J. L., Buters, J. T. M., Nelson, S. D., et al. (1996). Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 9:1159-1166.
18. Brinker, A. D., Wassel, R. T., Lyndly, J., Serrano, J., Avigan, M., Lee, W. M., et al. (2009). Telithromycin-associated hepatotox-icity: clinical spectrum and causality assessment of 42 cases. Hepatology 49:250-257.
19. Brune, K. (2007). Persistence of NSAIDs at efect sites and rapid disappearance from side-efect compartments contributes to toler-ability. Curr Med Res Opin 23:2985-2995.
20. Caraco, Y., Blotnick, S., Muszkat, M. (2008). CYP2C9 genotype-guided warfarin prescribing enhances the efcacy and safety of antico-agulation: a prospective, randomized, controlled study. Clin Pharmacol Ter 83:460-470.
21. Carlson, T. J., Fisher, M. B. (2008). Recent advances in high-throughput screening for ADME properties. Comb Chem High Troughput Screen 11:258-264.
22. Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T. , Serrano, J., et al. (2008). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135:1924-1934.
23. Chen, C., Krausz, K. W., Shah, Y. M., Idle, J. R., Gonzalez, F. J. (2009). Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARα activation as a contributing mechanism of acetaminophen-induced hepatotox-icity. Chem Res Toxicol 22:699-707.
24. Chen, Q., Doss, G. A., Tung, E. C., Liu, W., Tang, Y. S., Braun, M. P., et al. (2006). Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identifcation of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos 34:145-151.
25. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., et al. (2002). Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914.
26. Chen, W., Shockcor, J. P., Tonge, R., Hunter, A., Gartner, C., Nelson, S. D. (1999). Protein and nonprotein cysteinyl thiol modifcation by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 38:8159-8166.
27. Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-1077.
28. Clercq, E. D. (2009). Anti-HIV drugs: 25 compounds approvde within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307-320.
29. Colacino, J. M. (1996). Mechanism for the anti-hepatitis B virus activity and mitochondrial toxicity if faluridine (FIAU). Antiviral Res 29:125-139.
30. Cote, J-F., Kirzin, S., Kramar, A., Mosnier, J-F., Diebold, M-D., Soubeyran, I., et al. (2007). UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275.
31. Cullen, J. M., Miller, R. T. (2006). Te role of pathology in the identi-fcation of drug-induced hepatic toxicity. Exp Opin Drug Metab Toxicol 2:241-247.
32. Day, R. O., McLachlan, A. J., Graham, G. G., Williams, K. M. (1999). Pharmacokinetics of nonsteroidal anti-infammatory drugs in synovial fuid. Clin Pharmacokinet 36:191-210.
33. Day, S. H., Mao, A., White, R., Schulz-Utermoehl, T., Miller, R., Beconi, M. G. (2005). A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Meth 52:278-285.
34. de Leon, J., Susce, M. T., Murray-Carmichael, E. (2006). Te AmpliChip™ CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ter 10:135-151.
35. Debbage, P. (2009). Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15:153-172.
36. Degoul, F., Sutton, A., Mansouri, A., Cepanec, C., Degott, C., Fromenty, B., et al. (2001). Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcohol liver disease. Gastroenterology 120:1468-1474.
37. DeLeve, L. D., Kaplowitz, N. (1991). Glutathione metabolism and its role in hepatotoxicity. Pharm Ter 52:287-305.
38. DeSanty, K. P., Amabile, C. M. (2007). Antidepressant-induced liver injury. Ann Pharmacother 41:1201-1211.
39. Dieckhaus, C. M., Fernandez-Metzler, C. L., King, R., Krolikowski, P. H., Baillie, T. A. (2005). Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 18:630-638.
40. Drummond, D. C, Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
41. Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C, et al. (2008). In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103:335-345.
42. Eastin, W. C, Haseman, J. K., Mahler, J. F., Bucher, J. R. (1998). Testing compounds in genetically altered mice. Toxicol Pathol 26:461-473.
43. Erives, G. V., Lau, S. S., Monks, T. J. (2008). Accumulation of neurotoxic thioether metabolites of 3,4-(±)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ter 324:284-292.
44. Evans, D. C, Watt, A. P., Nicoll-Grifth, D. A., Baillie, T. A. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16.
45. Evista®. Prescribing information. (2008) Available at: www.evista.com. (Accessed January 10, 2009).
46. Fernandes, N, Geller, S. A., Fong, T-L. (1998). Terbinafne hepatotoxic-ity: case report and review of the literature. Am J Gastroenterol 93:459-460.
47. Fernandes, N. F., Martin, R. R., Schenker, S. (2000). Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol 95:532-535.
48. FDA. (2009). Tables of valid genomic biomarkers in the context of approved drug labels. Available at: www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/default. htm. (Accessed January 17 2009).
49. Funk, C, Pantze, M., Jehle, L., Ponelle, C, Scheuermann, G., Lazendic, M., et al. (2001a). Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats: correlation with the gender diference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (BSEP) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
50. Funk, C., Ponelle, C., Scheuermann, G., Pantze, M. (2001b). Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (BSEP) in the rat. Mol Pharmacol 59:627-635.
51. Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C, Humphreys, W. G (2009). In vitro screening of 50 highly prescribed drugs for thiol adduct formation\-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol 22:690-698.
52. Ghanbari, F., Rowland-Yeo, K., Bloomer, J. C, Clarke, S. E., Lennard, M. S., Tucker, G. T, et al. (2006). A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
53. Glatt, H. (1997). Bioactivation of mutagens via sulfation. FASEB J 11:314-321.
54. Greaves, P., Williams, A., Eve, M. (2004). First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 3:226-236.
55. Greene, D. S., Barbhaiya, R. H. (1997). Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33:260-275.
56. Guengerich, F. P., MacDonald, T. L. (1990). Mechanism of cytochrome P-450 catalysis. FASEB J 4:2453-2459.
57. Hagmann, W. K. (2008). Te discovery of taranabant, a selective can-nabinoid-1 receptor inverse agonist for the treatment of obesity. Arch Pharm Chem Life Sci 341:405-411.
58. Hanna, P. E. (1996). Metabolic activation and detoxifcation of arylamines. Curr Med Chem 3:195-210.
59. Hargus, S. J., Martin, B. M., George, J. W., Pohl, L. R. (1995). Covalent modifcation of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-infammatory drug, diclofenac. Chem Res Toxicol 8:993-996.
60. He, K., Woolf, T. F., Hollenberg, P. F. (1999). Mechanism-based inac-tivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ter 288:791-797.
61. Herceptin. Package insert. 2003) Available at: www.genentechaccess- solutions.com/herceptin/professional/forms/PI.jsp. (Accessed February 7 2009).
62. Hinson, J. A., Reid, A. B., McCullough S. S., James, L. P. (2004). Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 36:805-822.
63. Hinz, B., Brune, K. (2008). Can drug removals involving cyclooxyge-nase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 29:391-397.
64. Honma, W., Shimada, M., Sasano, H., Ozawa, S., Miyata, M., Nagata, K., et al. (2002). Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949.
65. Huang, Y-S., Su, W-J., Huang, Y-H., Chen, C-Y., Chang, F-Y., Lin, H-C., et al. (2007). Genetic polymorphisms of manganese superox-ide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128-134.
66. Ito, K., Ogihara, K., Kanamitsu, S-I., Itoh, T. (2003). Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
67. Iverson, S. L., Uetrecht, J. P. (2001). Identifcation of a reactive metabolite of terbinafne: insights into terbinafne-induced hepatotoxic-ity. Chem Res Toxicol 14:175-181.
68. Jaeschke, H. (2005). Role of infammation in the mechanism of acetaminophen-induced hepatotoxicity. Exp Opin. Drug Metab Toxicol 1:389-397.
69. Jaeschke, H., Bajt M. L. (2006). Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 89:31-41.
70. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., Lemasters, J. J. (2002). Mechanisms of hepatotoxic-ity. Toxicol Sci 65:166-176.
71. James, L. P., Capparelli, E. V., Simpson, P. M., Letzig, L., Roberts, D., Hinson, J. A., et al. (2008). Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ter 84:684-690.
72. Jones, A. F., Vale, J. A. (1993). Paracetamol poisoning and the kidney. J Clin Pharm Ter 18:5-8.
73. Jones, D. C., Duvauchelle, C. D., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., et al. (2005). Serotonergic neurotoxic metabolites of ecstasy identifed in rat brain. J Pharmacol Exp Ter 313:422-431.
74. Kaitin, K. I. (2008). Obstacles and opportunities in new drug development. Clin Pharmacol Ter 83:210-212.
75. Kalgutkar, A. S., Soglia, J. R. (2005). Minimizing the potential for metabolic activation in drug discovery. Exp Opin Drug Metab Toxicol 1:91-142.
76. Kalgutkar, A. S., Vaz, A. D. N., Lame, M. E., Henne, K. R., Soglia, J., Zhao, S. X., et al. (2005). Bioactivation of the nontricyclic anti-depressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 33:243-253.
77. Kashimshetty, R., Desai, V. G., Kale, V. M., Lee, T., Moland, C. L., Branham, W. S., et al. (2009). Underlying mitochondrial dysfunction triggers futamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmcol 238:150-159.
78. Kassahun, K., Hu, P., Grillo, M. P., Davis, M. R., Jin, L., Baillie, T. A. (1994). Metabolic activation of unsaturated derivatives of val-proic acid: identifcation of novel glutathione adducts formed through coenzyme A-dependent and-independent processes. Chem Biol Interact 90:253-275.
79. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., et al. (2001). Studies on the metabolism of troglita-zone to reactive intermediates in vitro and in vivo: evidence for novel bioactivation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-70.
80. Kenne, K., Skanberg, I., Glinghammar, B., Berson, A., Pessayre, D., Flinois, J-P., et al. (2008). Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730-746.
81. Ketterer, B., Mulder, G. (1990). Glutathione conjugation. In: Mulder, G. J. (Ed.), Conjugation reaction in drug metabolism (pp 307-364). New York: Taylor & Francis.
82. Khan, K. K., He, Y. Q., Correia, M. A., Halpert, J. R. (2002). Diferential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos 30:985-990.
83. Kleiner, D. E., Gafey, M. J., Sallie, R., Tsokos, M., Nichols, L., McKenzie, R., et al. (1997). Histopathology changes associated with faluridine hepatotoxicity. Mod Pathol 10:192-199.
84. Kumar, S., Kassahun, K., Tschirret-Guth, R. A., Mitra, K., Baillie, T. A. (2008). Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps, and future directions. Curr Opin Drug Discov Dev 11:43-52.
85. Kola, I. (2008). Te state of innovation in drug development. Clin Pharmacol Ter 83:227-230.
86. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 90:451-459.
87. Labbe, G., Pessayre, D., Fromenty, B. (2008). Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fund Clin Pharmacol 22:335-353.
88. Lewis, W., Griniuviene, B., Tankersley, K. O., levine, E. S., Montione, R., Engelman, L., et al. (1997). Depletion of mitochon-drial DNA, destruction of mitochondria, and accumulation of lipid droplets result from faluridine treatment in woodchucks (Marmota monax). Lab Invest 76:77-87.
89. Li, C., Olurinde, M. O., Hodges, L. M., Grillo M. P., Benet, L. Z. (2003). Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. Drug Metab Dispos 31:727-730.
90. Lim, H. K., Chen, J., Cook, K., Sensenhauser, C., Silva, J., Evans, D. C. (2008). A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. Rapid Commun Mass Spectrom 22:1295-1311.
91. Lin, J. H. (1999). Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev 39:33-49.
92. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F. , et al. (2008). SLCO1B1 variants and statin-induced myopathy\-a genomewide study. NEJM 359:789-799.
93. Liu, X., Chen, C., Smith, B. J. (2008). Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ter 325:349-356.
94. Liu, Z-X., Kaplowitz, N. (2006). Role of innate immunity in acetami-nophen-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 2:493-503.
95. Lucena, M. I., Carvajal, A., Andrade, R. J., Velasco, A. (2003). Antidepressant-induced hepatotoxicity. Exp Opin Drug Saf 2:249-262.
96. Madan, A., Usuki, E., Burton, A., Ogilvie, B. W., Parkinson, A. (2002). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In:Rodrigues, A. D. (Ed.), Drug-drug interactions (pp 217-294). New York: Marcel Dekker.
97. Mallat, A., Zafrani, E. S., Metreau, J. M., Dhumeaux, D. (1997). Terbinafne-induced prolonged cholestasis with reduction of interlobular bile ducts. Digest Dis Sci 42:1486-1488.
98. Mallikaarjun, S., Salazar, D. E., Bramer, S. L. (2004). Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44:179-187.
99. Manyike, P. T., Kharasch, E. D., Kalhorn, T. F., Slattery, J. T. (2000). Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ter 67:275-282.
100. Martin, J. L., Plevak, D. J., Flannery, K. D., Charlton, M., Poterucha, J. J., Humphreys, C. E., et al. (1995). Hepatotoxicity after desfurane anesthesia. Anesthesiology 83:1125-1129.
101. Masubuchi, Y. (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347-356.
102. McKenzie, R., Fried M. W., Sallie, R., Conjeevaram, H., DiBisceglie, A. M., Park, Y., et al. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investiga-tional nucleoside analogue for chronic hepatitis B. NEJM 333:1099-1105.
103. Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008b). Circulating micro-RNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513-10518.
104. Mitchell, M. D., Elrick, M. M., Walgren, J. L., Mueller, R. A., Morris, D. L., Tompson, D. C. (2008a). Peptide-based in vitro assay for the detection of reactive metabolites. Chem Res Toxicol 21:859-868.
105. Monks, T. J., Lau, S. S. (1994). Glutathione conjugation as a mechanism for the transport of reactive metabolites. Adv Pharmacol 27:183-210.
106. Monks, T. J, Lau, S. S. (1998). Te pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu Rev Pharmacol Toxicol 38:229-255.
107. Mortishire-Smith, R. J., Skiles, G. L., Lawrence, J. W., Spence, S., Nicholls, A. W., Johnson, B. A., et al. (2004). Use of metabonom-ics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem Res Toxicol 17:165-173.
108. Muldrew, K. L., James, L. P., Coop, L., McCullough, S. S., Hendrickson, H. P., Hinson, J. A., et al. (2002). Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 30:446-451.
109. Mullin, R. (2003). Drug development costs about $1.7 billion. Chem Eng News 81:8.
110. Myers, T. G., Dietz, E. C., Anderson, N. L, Khairallah, E. A., Cohen, S. D., Nelson, S. D. (1995). A comparative study of mouse liver protein arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'-hydroxyacetanilide. Chem Res Toxicol 8:403-413.
111. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., et al. (2009). A zone clarifcation system for risk assessment of idiosyncratic toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970-1977.
112. Neuberger, J. M. (1990). Halothane and hepatitis: incidence, predisposing factors, and exposure guidelines. Drug Saf 5:28-38.
113. Niemi, M., Schaefeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., et al. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440.
114. Njoku, D., Laster, M. J., Gong, D. H., Eger II, E. I., Reed, G. F., Martin, J. L. (1997). Biotransformation of halothane, enfurane, isofurane, and desfurane to trifuoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 84:173-178.
115. Obach, R. S., Kalgutkar, A. S., Soglia, J. R., Zhao, S. X. (2008). Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21:1814-1822.
116. Olson, H., Betton, G., Robinson, D., Tomas, K., Monro, A., Kolaja, G., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67.
117. Ong, M. M. K., Latchoumycandane, C., Boelsterli, U. A. (2006). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97:205-213.
118. Oritiz de Montellano, P. R. (1989). Cytochrome P450 catalysis: radical intemediates and dehydrogenation reactions. Trends Pharmacol Sci 10:354-359.
119. Overdevest, J. B., Teodorescu, D., Lee, J. K. (2009). Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem 55:684-697.
120. Palovaara, S., Kivisto, K. T., Tapanainen, P., Manninen, P., Neuvonen, P., Laine, K. (2000). Efect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Clin Pharmacol 50:333-337.
121. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., Niemi, M. (2006). SLCO1B1 plotmorphism markedly afects the pharmacokinetics of simvastatin acid. Pharmacogenet Genom 16:873-879.
122. Pohl, L. R. (1990). Drug-induced allergic hepatitis. Semin Liver Dis 10:305-315.
123. Pohl, L. R., Branchflower, R. V. (1981). Covalent binding of elec-trofilic metabolites to macromolecules. Meth Enzymol 77:43-50.
124. Polasek, T. M., Miners, J. O. (2006). Quantitative prediction of mac-rolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Pharmacokint Dispos 62:203-208.
125. Ponchaut, S., van Hoof, F., Veitch, K. (1992). In vitro efects of val-proate and valproate metabolites on mitochondrial oxidations: relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 43:2435-2442.
126. Prakash, C., Sharma, R., Gleave, M., Nedderman, A. (2008). In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr Drug Metab 9:952-964.
127. Rashed, M. S., Myers, T. G., Nelson, S. D. (1990). Hepatic protein arylation, glutathione depletion, and metabolites profles of acetaminophen and a non-hepatotoxic regioisomer, 3'-hydroxy-acetanilide, in the mouse. Drug Metab Dispos 18:765-770.
128. Raskind, J. Y., El-Chaar, G. M. (2000). Te role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34:630-638.
129. Rieder, M. J. (2009). Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Exp Opin Drug Saf 8:331-343.
130. Rodrigues, A. D., Winchell, G. A., Dobrinska, M. R. (2001). Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 41:368-373.
131. Roth, R. A., Luyendyk, J. P., Maddox, J. F., Ganey, P. E. (2003). Infammation and drug idiosyncrasy\-is there a connection? J Pharmacol Exp Ter 307:1-8.
132. Ruepp, S. U., Tonge, R. P., Shaw, J., Wallis, N., Pognan, F. (2002). Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65:135-150.
133. Samuel, K., Yin, W., Stearns, R. A., Tang, Y. S., Chaudhary, A. G., Jewell, J. P., et al. (2003). Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom 38:211-221.
134. Sanderson, J. P. , Naisbitt, D. J., Park, B. K. (2006). Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J 8:E55-E64.
135. Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., Giardina, B. (2007). Te role of mitochondria in pharmacotoxicology: a reevalua-tion of an old, newly emerging topic. Am J Physiol Cell Physiol 293:C12-C21.
136. Shakeri-Nejad, K., Stahlmann, R. (2006). Drug interactions during therapy with three major groups of antimicrobial agents. Exp Opin Pharmacother 7:639-651.
137. Shenton, J. M., Popovic, M., Chen, J., Masson, M. J., Uetrecht, J. P. (2005). Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown Norway rat. Chem Res Toxicol 18:1799-1813.
138. Silva, M. F. B., Ijst, L., Allers, P., Jakobs, C., Duran, M., de Almeida, I. T., et al. (2004). Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metab Dispos 32:1304-1310.
139. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplifcation of the HER2-2/neu onco-gene. Science 235:177-182.
140. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against Hers for metastatic breast cancer that overexpresses Hers. NEJM 344:783-792.
141. Slavin, D. E., Schlichting, C. L., Freston, J. W. (2005). Rating the severity of the medical consequences of drug-induced liver injury. Regul Toxicol Pharmacol 43:134-140.
142. Smith, M. T. (2003). Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16:679-687.
143. Somchit, N., Wade, L. T., Ramsay, L., Goldin, R. D., Kenna, J. G., Caldwell, J. (1997). Hepatotoxicity and hepatic protein adduct formation in rats dosed i.p. with diclofenac. Hum Exp Toxicol 16:401.
144. Spahn-Langguth, H., Benet L. Z. (1992). Acyl glucuronides revisited: is the glucuronidation process a toxifcation as well as detoxifca-tion mechanism? Drug Metab Rev 24:5-48.
145. Stern, S. T., Bruno, M. K., Hennig, G. E., Horton, R. A., Roberts, J. C., Cohen, S. D. (2005a). Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: I. Enhancement of acetaminophen nephrotoxicity by acetaminophen-cysteine. Toxicol Appl Pharmacol 202:151-159.
146. Stern, S. T., Bruno, M. K., Horton, R. A., Hill, D. W., Roberts, J. C., Cohen, S. D. (2005b). Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: II. Possible involvement of the γ-glutamyl cycle. Toxicol Appl Pharmacol 202:160-171.
147. Summa, V., Petrocchi, A., Bonelli, F. , Crescenzi, B., Donghi, M., Ferrara, M, et al. (2008). Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-aids infection. J Med Chem 51:5843-5855.
148. Sun, J., Schnackenberg, L. K., Holland, R. D., Schmitt, T. C., Cantor, G. H., Dragan, Y. P., et al. (2008). Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J Chromatogr B 871:328-340.
149. Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., et al. (2008). Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos 36:1770-1779.
150. Tang, W. (2003). Te metabolism of diclofenac\-enzymology and toxicology perspectives. Curr Drug Metab 4:319-329.
151. Tang, W. (2007). Drug metabolite profling and elucidation of drug-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 3:407-420.
152. Tang, W., Abbott, F. S. (1996). Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuro-nidation: LC/MS/MS characterization of the GSH-glucuronide di-conjugates. Chem Res Toxicol 9:517-526.
153. Tang, W., Borel, A. G., Abbott, F. S. (1996). Conjugation of glutath-ione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione S-transferases. Drug Metab Dispos 24:436-446.
154. Tang, W., Lu, A. Y. H. (2009). Drug metabolism and pharmacokinetics in support of drug design. Curr Pharm Des 15:2170-2183.
155. Tang, W., Stearns, R. A., Wang, R. W., Miller, R. R., Chen, Q., Ngui, J., et al. (2008). Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists. Xenobiotica 38:1437-1457.
156. Tennant, B. C., Baldwin, B. H., Graham, L. A., Ascenzi, M. A., Hornbuckle, W. E., Rowland, P. H., et al. (1998). Antiviral activity and toxicity of faluridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179-191.
157. Tirmenstein, M. A., Nelson, S. D. (1989). Subcellular binding and efects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J Biol Chem 264:9814-9819.
158. Tong, V. , Teng, X. W., Chang, T. K. H., Abbott, F. S. (2005). Valproic acid II: efects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 86:436-443.
159. Townsend, D. M., Hanigan, M. H. (2002). Inhibition of γ-glutamyl transpeptidase or cysteine S-conjugate β-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ter 300:142-148.
160. Townsend, D. M., Tew, K. D., He, L., King, J. B., Hanigan, M. H. (2009). Role of glutathione S-transferase Pi in cisplatin-induced nephro-toxicity. Biomed Pharmacother 63:79-85.
161. Uetrecht, J. (1999). New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 12:387-395.
162. Uetrecht, J. (2006). Evaluation of which reactive metabolite, if any, is responsible for a specifc idiosyncratic reaction. Drug Metab Rev 38:745-753.
163. Uetrecht, J. (2009). Immune-mediated adverse drug reactions. Chem Res Toxicol 22:24-34.
164. Umrethia, M., Ghosh, P., Majithya, R., Murthy, R. (2007). 6-mercap-topurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Cancer Invest 25:117-123.
165. Venkatakrishnan, K., Obach, R. S. (2007). Drug-drug interaction via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharma-cologic evaluation. Curr Drug Metab 8:449-462.
166. Waley, S. G. (1985). Kinetics of suicide substrates: practical procedures for determining parameters. Biochem J 227:843-849.
167. Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., et al. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106:4402-4407.
168. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Maurel, P., Guzelian, P. S. (1986). Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 261:6264-6271.
169. Westphal, J. F. (2000). Macrolide-induced clinically relevant drug interactions with cytochrome P450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin. Br J Clin Pharmacol 50:285-295.
170. Wen, B., Ma, L., Rodrigues, D., Zhu, M. (2008a). Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos 36:841-850.
171. Wen, B., Ma, L., S. D. Nelson, S.D., Zhu, M. (2008b). High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Anal Chem 80:1788-1799.
172. Williams, D. P. (2006). Toxicophores: investigations in drug safety. Toxicology 226:1-11.
173. Yamamoto, Y., Nakajima, M., Yamazaki, H., Yokoi, T. (2001). Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 70:471-482.
174. Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., et al. (1999). Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.
175. Yuan, L., Kaplowitz, N. (2009). Glutathione in liver disease and hepa-totoxicity. Mol Asp Med 30:29-41.
176. Zhang, Z., Chen, Q., Li, Y., Doss, G. A., Dean, B. J., Ngui, J. S., et al. (2005). In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinine-type metabolites. Chem Res Toxicol 18:675-685.
177. Zhang, Z., Gan, J. (2007). Protocols for assessment of in vitro and in vivo bioactivation potential of drug candidates. In:Zhang, D., Zhu, M., Humphreys, W. G. (Eds.), Drug metabolism in drug design and development: basic concepts and practice (pp 447-476). Hoboken, New Jersey, USA: John Wiley & Sons.
178. Zhang, Z., Zhu, M., Tang, W. (2009). Metabolite identifcation and pro-fling in drug design: current practice and future directions. Curr Pharm Des 15:2220-2235.
179. Zuckermann, J. M. (2004). Macrolides and ketolides: azithro-mycin, clarithromycin, telithromycin. Infect Dis Clin N Am 18:621-649.